Emerging biomarkers in urothelial carcinoma: Challenges and opportunities Review


Authors: Andreatos, N.; Iyer, G.; Grivas, P.
Review Title: Emerging biomarkers in urothelial carcinoma: Challenges and opportunities
Abstract: Advanced urothelial carcinoma (UC) is a very important cause of cancer-related morbidity and mortality with, until recently, only a few available therapeutic options. The treatment landscape has dramatically changed in recent years with the introduction of immune checkpoint inhibitors and the development of novel targeted agents, such as erdafitinib, and antibody-drug conjugates, such as enfortumab vedotin. Cost-effective utilization of this rapidly expanding therapeutic armamentarium can be further optimized via the identification and validation of reliable prognostic and predictive biomarkers that inform prognostication and patient selection. In this review, we aim to summarize examples of recent developments in the rapidly expanding field of emerging biomarkers in UC, outlining challenges and opportunities. © 2020
Keywords: signal transduction; vasculotropin; gene mutation; lenalidomide; bevacizumab; cisplatin; validation process; biomarkers; biological marker; dna repair; gene overexpression; ipilimumab; progression free survival; ddr; protein p53; immune response; immunotherapy; immunogenicity; cystectomy; pazopanib; neoadjuvant chemotherapy; growth factor; loss of function mutation; transitional cell carcinoma; transcriptome; everolimus; lapatinib; cd33 antigen; bladder; programmed death 1 ligand 1; programmed death 1 receptor; cyclin dependent kinase 6; trial; clinical trial (topic); b raf kinase inhibitor; phase 2 clinical trial (topic); cancer prognosis; cabozantinib; human; priority journal; article; pembrolizumab; durvalumab; ercc2 gene; erdafitinib; atezolizumab; antibody drug conjugate; ngs; enfortumab vedotin; nectin
Journal Title: Cancer Treatment and Research Communications
Volume: 25
ISSN: 2468-2942
Publisher: Elsevier Inc.  
Date Published: 2020-01-01
Start Page: 100179
Language: English
DOI: 10.1016/j.ctarc.2020.100179
PROVIDER: scopus
PUBMED: 32920502
PMCID: PMC8387954
DOI/URL:
Notes: Article -- Export Date: 1 October 2020 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Gopakumar Vasudeva Iyer
    342 Iyer